Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Grants Breakthrough Therapy Designation to IMGN632 in Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

October 5th 2020

The FDA has granted a breakthrough therapy designation to IMGN632 for the treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.

Dr. Bhat on the Role of Targeted Therapies in CLL

October 2nd 2020

Seema A. Bhat, MD, hematologist, discusses the role of targeted therapies in chronic lymphocytic leukemia.

FDA Issues Complete Response Letter for Remestemcel-L for Pediatric Steroid-Refractory Acute GVHD

October 2nd 2020

The FDA has issued a complete response letter to Mesoblast Limited regarding a biologics license application for remestemcel-L, recommending that at least 1 additional randomized, controlled study be conducted in adult and/or pediatric patients to provide further evidence of the efficacy of the agent in steroid-refractory acute graft-versus-host disease.

FDA Approval Insights: Tazemetostat in Relapsed/Refractory Follicular Lymphoma

October 1st 2020

In our exclusive interview, Dr. Leonard discusses the FDA approval of tazemetostat in patients with relapsed/refractory follicular lymphoma whose tumors are EZH2 positive, as well as those with relapsed/refractory follicular lymphoma who have no other available satisfactory treatment options, and the benefits of providing another agent for this subset of patients.

Experts Examine Predictive Value of MRD, Maintenance Strategies in Myeloma

September 30th 2020

Nina Shah, MD, and Sandy Wong, MD, discuss the predictive value of minimal residual disease and a potential course of treatment for a patient with revised International Staging System I multiple myeloma.

Selinexor May Offer Post–CAR T Potential in Relapsed/Refractory DLBCL

September 30th 2020

Kami Maddocks, MD, discusses the significance of the selinexor approval in the diffuse large B-cell lymphoma treatment paradigm, emerging strategies that seek to address unmet needs, and remaining sequencing questions.

Dr. Maddocks on Ongoing Sequencing Challenges in DLBCL

September 23rd 2020

Kami J. Maddocks, MD, discusses ongoing sequencing challenges in diffuse large B-cell lymphoma.

Dr. Burke on the Potential of Time-Limited BTK Inhibitor Therapy in B-Cell Malignancies

September 23rd 2020

John M. Burke, MD, discusses the potential benefits of time-limited therapy with BTK inhibitors in B-cell malignancies.

Dr. Hill on the Impact of Recent Approvals in Relapsed/Refractory DLBCL

September 23rd 2020

Brian T. Hill, MD, PhD, discusses the impact of recent regulatory approvals in relapsed/refractory diffuse large B-cell lymphoma.

AUTO3 CAR T-Cell Product Plus Pembrolizumab Shows Clinical Activity, Tolerability in Relapsed/Refractory DLBCL

September 23rd 2020

The investigational CAR T-cell product AUTO3 in combination with pembrolizumab was found to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

FDA Grants Priority Review to Crizotinib for Pediatric ALK+ Anaplastic Large Cell Lymphoma

September 23rd 2020

The FDA has granted a priority review to a supplemental new drug application for crizotinib in the treatment of pediatric patients with ALK-positive relapsed/refractory systemic anaplastic large cell lymphoma.

FDA Approval Sought for Loncastuximab Tesirine for Relapsed/Refractory DLBCL

September 22nd 2020

A biologics license application has been submitted to the FDA for loncastuximab tesirine for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Dr. Deol on the Nuances of Utilizing CAR T-Cell Therapy in Lymphoma and Leukemia

September 22nd 2020

Abhinav Deol, MD, discusses the nuances of utilizing CAR T-cell therapy in lymphoma and leukemia.

Venetoclax Raises the Bar in Newly Diagnosed AML Ineligible for Intensive Chemotherapy

September 17th 2020

Catherine Lai, MD, MPH, discusses the significance of venetoclax in the acute myeloid leukemia treatment paradigm, the data from the VIALE-A trial, and remaining challenges faced in practice.

Emerging Approaches for Myelodysplastic Syndromes

September 17th 2020

Oncologists who specialize in the treatment of hematologic malignancies participated in a virtual workshop to discuss the emerging treatment landscape in myelodysplastic syndromes.

FDA Grants Breakthrough Therapy Designation to Magrolimab for MDS

September 15th 2020

The FDA has granted a breakthrough therapy designation to magrolimab for the treatment of patients with newly diagnosed myelodysplastic syndrome.

Dr. Maddocks on the Role of Tazemetostat in EZH2-Mutant Follicular Lymphoma

September 14th 2020

Kami J. Maddocks, MD, discusses the role of tazemetostat in patients with EZH2-mutant follicular lymphoma.

Brentuximab Vedotin Shows Broadening Benefit Across Lymphoma Subtypes

September 14th 2020

Aarthi Shenoy, MD, discusses how the emergence of the antibody-drug conjugate, brentuximab vedotin, has had a positive impact on improving overall survival and progression-free survival for patients with T-cell lymphomas and classical Hodgkin lymphoma.

BTK Inhibitors Revolutionize Treatment in B-Cell Malignancies, But Require AE Awareness

September 11th 2020

Shuo Ma, MD, PhD, discusses the evolving role of BTK inhibitors in B-cell malignancies, ongoing research efforts examining their use, safety concerns to be aware of with the agents, and next steps for research.

Leslie Breaks Down the Growing Importance of BTK Inhibitors in B-Cell Malignancies

September 11th 2020

Lori A. Leslie, MD, highlights ibrutinib, acalabrutinib, and zanubrutinib, the 3 FDA approved BTK inhibitors that have become very important weapons in the treatment arsenal for B-cell malignancies.